Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Change in Acquisitions & Divestments: 2021-2024

Historic Change in Acquisitions & Divestments for Stoke Therapeutics (STOK) over the last 4 years, with Dec 2024 value amounting to $60.0 million.

  • Stoke Therapeutics' Change in Acquisitions & Divestments rose 65.76% to $33.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.2 million, marking a year-over-year increase of 115.30%. This contributed to the annual value of $60.0 million for FY2024, which is 44.22% down from last year.
  • Stoke Therapeutics' Change in Acquisitions & Divestments amounted to $60.0 million in FY2024, which was down 44.22% from $107.6 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Change in Acquisitions & Divestments registered a high of $159.4 million during FY2022, and its lowest value of $12.0 million during FY2021.
  • Its 3-year average for Change in Acquisitions & Divestments is $109.0 million, with a median of $107.6 million in 2023.
  • Per our database at Business Quant, Stoke Therapeutics' Change in Acquisitions & Divestments soared by 1,228.33% in 2022 and then tumbled by 44.22% in 2024.
  • Over the past 4 years, Stoke Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $12.0 million in 2021, then surged by 1,228.33% to $159.4 million in 2022, then crashed by 32.52% to $107.6 million in 2023, then crashed by 44.22% to $60.0 million in 2024.